CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4MlWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D020246 Venous Thrombosis NIH 0.32
D011655 Pulmonary Embolism NIH 0.32
D004617 Embolism NIH 0.30
D013927 Thrombosis NIH 0.23

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0002625 Deep venous thrombosis HPO 0.32
HP:0002204 Pulmonary embolism HPO 0.32

There is one clinical trial.

Clinical Trials

1 Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial

The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

NCT04400799 COVID-19 Pulmonary Embolism, Deep Vein Thrombosis Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml
MeSH:Pulmonary Embolism Thrombosis Embolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Venous thrombosis

Primary Outcomes

Measure: hospitalizations

Time: 30 days

Measure: all-cause death

Time: 30 days

Secondary Outcomes

Description: including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke

Measure: Number of cardiovascular events

Time: within 14 days, 30 days, and 90 days of randomization

Measure: any hospitalizations

Time: within 14 days, 30 days, and 90 days of randomization

Measure: all-cause death

Time: within 14 days, 30 days, and 90 days of randomization

Description: measured by number of cardiovascular events, and major bleeding

Measure: Net clinical benefit

Time: within 14 days, 30 days, and 90 days of enrolment.

Description: ISTH criteria, in-hospital diagnosis

Measure: Disseminated intravascular coagulation

Time: within 14 days, 30 days, and 90 days of enrolment

Related HPO nodes (Using clinical trials)

HP:0002625: Deep venous thrombosis
Genes 18
HABP2 AKT1 SERPINC1 F9 MTRR SERPIND1 PIEZO1 PMM2 PROS1 PLAT PROC F2 PROC THBD F13A1 F5 SERPINC1 MTHFR
Protein Mutations 3
G20210A G21210A R506Q
SNP 0
HP:0002204: Pulmonary embolism
Genes 43
HABP2 IL23R IL12A SERPINC1 HLA-B CBS ERAP1 KCNJ5 PROS1 SMAD4 GNAQ CCR1 PROC ACVRL1 F2 PROC PTEN SERPINC1 MTHFR KLRC4 ENG CD55 GDF2 AKT1 TET2 PLP1 MEFV C4A IL12A-AS1 MPL AGGF1 UBAC2 TLR4 PROS1 PROC IL10 F13A1 PIGA FAS GNAQ JAK2 PROS1 STAT4
Protein Mutations 2
G20210A G21210A
SNP 0
HP:0004936: Venous thrombosis
Genes 99
IL12A CASR FGA PGM1 JAK2 PTEN SERPINC1 PIGM PTH1R GDF2 TET2 IDH1 MEFV IL12A-AS1 CTLA4 PDGFRA IL10 IDH2 THPO GNAQ CPA1 FGG STAT4 SH2B3 KCNN4 IL23R MTRR CBS ERAP1 SAA1 PROS1 SMAD4 PLAT CALR CCR1 MPL ACVRL1 F2 PROC KLRC4 AKT1 CDH23 SPINK1 CTRC AKT1 PTPN22 PROS1 TP53 PROC PRSS1 MPL HBB THBD EPOR PRTN3 CALR PROS1 PRSS2 IDH1 HLA-B SERPIND1 JAK2 PRKAR1A KIF11 PDE4D IDH2 F9 C4A AGGF1 UBAC2 PIEZO1 F13A1 PIEZO1 CFTR HABP2 SERPINC1 GNAQ PROC MPL FGB MTHFR ENG CD55 JAK2 HLA-DPB1 SLC4A1 HLA-DPA1 NOTCH1 MET TET2 MPL TLR4 CTNNB1 PMM2 F5 USP8 FAS TET2 JAK2
Protein Mutations 0
SNP 0